Faron Pharmaceuticals Oy (LSE:FARN) - Share price - Overview

Stock Report

Faron Pharmaceuticals Oy FARN

Last Price
GBX710.00

Day Change
10.00|1.43%

As of 28/07/2017
12:07:51 BST | GBX
Minimum 15 Minutes Delay.

Last Close700.00p
Day Range680.00 - 710.00
Mkt Cap195.40Mil
52-Wk Range244.50 - 825.00
Yield %0.00
ISINFI4000153309
Volume2,500
P/E-22.23
P/S180.34
P/CF-24.59

Share Price

Total Returns 27/07/2017

 Chg (%)  
More ...
Faron Pharmaceuticals Oy-2.78 
FTSE 100 TR GBP0.20
 
Financials
201420152016
More ...
Income Statement
Turnover0.740.380.94
Operating Profit-1.00-4.24-7.26
Net Profit-1.11-4.50-7.61
Reported EPS-4.87-21.80-31.94
Balance Sheet
Current Assets0.7710.1613.94
Non Current Assets0.930.760.81
Total Assets1.6910.9214.76
Current Liabilities1.301.623.73
Total Liabilities2.622.695.47
Total Equity-0.938.249.29
Cash Flow
Operating Cash Flow-0.31-4.96-6.57
Net Change in Cash0.207.870.34
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
2017-8.20-31.45--22.26---
2018-6.07-23.33--30.00---
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
25/04/2017PurchaseDr. Jonathan Knowles635.001,0006,350.00
31/03/2017PurchaseDr. Jonathan Knowles550.0019,000104,500.00
13/12/2016PurchaseDr. Jonathan Knowles275.0010,00027,500.00
12/12/2016PurchaseDr. Jonathan Knowles265.007,00018,550.00

Company Profile

Faron Pharmaceuticals Oy is a clinical stage drug discovery and development company. The Company creates novel treatments for medical conditions with unmet needs.

Sector

Biotechnology

Market Position

717 of 1846 Companies

Index

FTSE AIM All Share

Outlook

(19/04/2017) ch - "We look forward to an exciting 2017"

Next Event 06/09/2017

Next interim announcement
Ratios
CompSecMkt
More ...
PER (E)-26.0813.8316.69
Div Yld (E)0.003.974.14
PEG (E)0.000.531.21
ROCE-73.05175.5112.12
Op Mrgn-797.67-6.774.20
EPS Grwth0.0034.0930.78
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanDr. Frank Armstrong
Chief Executive OfficerDr. Markku Jalkanen
Chief Financial OfficerMr. Yrjo Wichmann
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.